56 results about "Beta hydroxybutyrate" patented technology

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol / L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

A system for optimising the production performance of a milk producing animal herd is provided. The system comprises a milk sampling apparatus, an analytical apparatus comprising separate equipment for analyzing compounds or parameters that in the presence of compounds indicative of the physiological or nutritional condition of the herd member, generates detectable signals, and apparatus directing a part of the milk sample (directing apparatus) to each separate equipment, which is controlled by data for the physiological and nutritional state of a herd member, so that the directing apparatus is only activated at pre-selected points in time or at pre-selected time intervals in the production and / or lactation cycles. Specific compounds are compounds indicative of mastitis, including beta-N-acetylhexosaminidase (NAGase) E.C. 3.2.1.52 and lactate dehydrogenase (LDH), protein balance, including milk urea nitrogen (MUN) and total protein, ketosis, including acetolactate, beta-hydroxybutyrate, acetone and lipids, fat and state in reproduction cycle, including a steroid or peptide hormone, e.g., progesterone. Furthermore, the system comprises equipment for signal detection to record and process the signals, equipment to store data and equipment to produce data output. Methods for optimizing the production performance of a milk producing animal herd and an apparatus therefor.

The invention discloses a biodegradable composite oxygen-barrier film and its preparation method and use. The biodegradable composite oxygen-barrier film is composed of at least two support layers and barrier layer which is located in each of the two support layers. Said support layer is selected from at least one of the following materials: polylactic acid, polybutylene succinate, polycaprolactone, poly(butylene adipate-co-terephthalate), poly(beta-hydroxybutyrate) and poly(beta-hydroxybutyrate-co-hydroxyvalerate); said barrier layers located in each of the two support layers are same or different, and the barrier layer is selected from poly(1,2-propylene carbonate) and nano-montmorillonite modified poly(1,2-propylene carbonate). The biodegradable composite oxygen-barrier film can be used as food or medicine package, and it will help to prolong shelf-life of food and medicine and the like; it can also prevent white-pollution.

Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D3, flavorant, or other excipient.

Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the S-enantiomer are formulated to control ketone body levels in a subject. The non-racemic mixture of BHB is enriched with the S-enantiomer to modulate the effect of ketone bodies in the subject and control the rate at which ketosis is achieved. In some aspects a composition for controlling ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, wherein the non-racemic mixture contains from about 52% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer and from about 48% to about 1% by enantiomeric equivalents of R-beta-hydroxybutyrate enantiomer.

The method for synthesizing completely-degradable plastics poly beta-hydroxybutyrate includes the folloiwng steps: adopting acetaldehyde as raw material to prepare beta-hydroxybutanal; oxidizing it to prepare beta-hydroxybutyric acid; esterifying it to prepare ethyl beta-hydroxybutyrate and polymerizing it to prepare poly beta-hydroxybutyrate. It is characterized by that preparation of beta-hydroxybutanal adopts benzene as solvent, sodium hydroxide as catalyst, its reaction temp. is 1-15 deg.C and the organic acid is used as neutralizing reagent, the preparation of beta-hydroxybutyric acid adopts ethyl acetate as solvent, cobalt acetate as catalyst, its reaction temp. is 40-100 deg.c and reaction pressure is 0.3-1.5 MPa, the preparation of ethyl ebeta-hydroxybutyrate adopts cresulsulfonic acid as catalyst and ethyl alcohol as solvent and polymerization preparation of beta-hydroxybutyrate uses isopropyl titanate as catalyst.

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and / or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.